The TFE Renal Cell Carcinoma (TFE RCC or tRCC) Research Initiatives is composed of physicians and researchers across the world working collaboratively to gather data and biological samples from patients in pursuit of better understanding TFE RCC and developing better treatment options and outcomes for patients everywhere.

Renal cell carcinoma is a rare form of kidney cancer, with TFE RCC being a specific subtype. TFE RCC makes up approximately half of all pediatric RCCs and up to 5% of adult RCCs. Currently, there are no formal treatment recommendations available for patients with TFE RCC and no dedicated therapeutic trials have been conducted. To more durably and rapidly advance clinical and biological insights, the TFE RCC Research Initiatives (TRRI) includes a registry and consortium focused on clinical and biological testing, tumor modeling, and novel drug testing.